Budralazine is a hydralazine-class antihypertensive agent used for the treatment of mild to moderate hypertension, either as monotherapy or in combination with hydrochlorothiazide. It directly relaxes vascular smooth muscle, leading to vasodilation and reduced peripheral resistance, thereby lowering blood pressure. Compared to hydralazine, it has a slower onset, longer duration of action, and causes less reflex tachycardia due to partial agonism at presynaptic α1-adrenergic receptors in cardiac sympathetic nerves. It increases cerebral, coronary, and renal blood flow during blood pressure reduction and demonstrates superior efficacy to hydralazine. Long-term use does not result in significant tolerance, and it is currently considered a third-line agent in hypertension management.